Mobile Infirmary First in Region to Treat In-Stent Restenosis with Innovative Drug-Coated Balloon

Mobile, Ala. – Infirmary Health’s Heart & Vascular Institute is proud to announce that Mobile Infirmary has become the first hospital in the region to utilize the newly FDA-approved AGENT™ Drug-Coated Balloon (DCB) by Boston Scientific for the treatment of coronary in-stent restenosis (ISR).

ISR occurs when a previously placed coronary stent becomes narrowed again, limiting blood flow to the heart. The AGENT DCB offers a novel solution by delivering a therapeutic drug directly to the arterial wall during balloon angioplasty, without leaving a permanent implant behind. This approach reduces the risk of additional complications and preserves future treatment options.

Dr. George Eyrich and Dr. Mina Jacob, interventional cardiologists with the Heart & Vascular Institute, successfully performed the first AGENT DCB procedures at Mobile Infirmary. These cases mark a significant milestone in advanced cardiac care along the Gulf Coast.

Mobile Infirmary’s adoption of the AGENT DCB aligns with the Heart & Vascular Institute’s mission to provide patients in south Alabama and surrounding areas with the most advanced cardiovascular treatment options available, close to home.

For more information about Infirmary Health’s cardiovascular services, visit infirmaryhealth.org.